|
CN1836048A
(en)
*
|
2003-06-10 |
2006-09-20 |
图尔金株式会社 |
Transducible DNA-binding proteins
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
ES2808687T3
(en)
|
2003-08-08 |
2021-03-01 |
Sangamo Therapeutics Inc |
Methods and compositions for directed cleavage and recombination
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
WO2005028630A2
(en)
|
2003-09-19 |
2005-03-31 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
JP4621142B2
(en)
|
2003-11-05 |
2011-01-26 |
株式会社癌免疫研究所 |
WT1-derived HLA-DR binding antigen peptide
|
|
DE102005026163A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Dade Behring Marburg Gmbh |
Antibodies directed against the Marburg I polymorphism of Factor VII activating protease (FSAP), their production and use
|
|
US20060063231A1
(en)
|
2004-09-16 |
2006-03-23 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
JP2009502170A
(en)
|
2005-07-26 |
2009-01-29 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Targeted integration and expression of foreign nucleic acid sequences
|
|
JP5266210B2
(en)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Modified cleavage half-domain
|
|
EP2447279B1
(en)
|
2006-05-25 |
2014-04-09 |
Sangamo BioSciences, Inc. |
Methods and compositions for gene inactivation
|
|
US9428756B2
(en)
|
2006-08-11 |
2016-08-30 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
|
WO2008060510A2
(en)
*
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
HUE029238T2
(en)
|
2006-12-14 |
2017-02-28 |
Dow Agrosciences Llc |
Optimized non-canonical zinc finger proteins
|
|
KR101598228B1
(en)
|
2007-02-27 |
2016-02-26 |
인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 |
Method for activation of helper t cell and composition for use in the method
|
|
ATE489465T1
(en)
|
2007-04-26 |
2010-12-15 |
Sangamo Biosciences Inc |
TARGETED INTEGRATION INTO THE PPP1R12C POSITION
|
|
CN101849010A
(en)
|
2007-06-29 |
2010-09-29 |
先锋高级育种国际公司 |
Methods for altering the genome of a monocot plant cell
|
|
EP2171052B1
(en)
|
2007-07-12 |
2014-08-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
US20110014616A1
(en)
|
2009-06-30 |
2011-01-20 |
Sangamo Biosciences, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
EP2188384B1
(en)
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
WO2009042164A1
(en)
|
2007-09-27 |
2009-04-02 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
|
WO2009054985A1
(en)
|
2007-10-25 |
2009-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
ES2459880T3
(en)
|
2008-04-14 |
2014-05-12 |
Sangamo Biosciences, Inc. |
Linear donor constructions for targeted integration
|
|
AU2009260888B2
(en)
|
2008-05-28 |
2014-09-11 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
EP2130836B1
(en)
*
|
2008-06-03 |
2013-02-13 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and methods for producing zinc fingers and concatemers thereof
|
|
US8597912B2
(en)
|
2008-06-10 |
2013-12-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of Bax-and Bak-deficient cell lines
|
|
KR20160015400A
(en)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
AU2009311697B2
(en)
|
2008-10-29 |
2014-12-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
WO2010065123A1
(en)
|
2008-12-04 |
2010-06-10 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
CA2747124C
(en)
|
2008-12-17 |
2018-09-04 |
Dow Agrosciences Llc |
Targeted integration into the zp15 locus
|
|
JP5827132B2
(en)
|
2009-02-04 |
2015-12-02 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for treating neuropathy
|
|
EP2408921B1
(en)
|
2009-03-20 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
JP5866283B2
(en)
|
2009-07-28 |
2016-02-17 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Methods and compositions for treating trinucleotide repeat disease
|
|
KR102262704B1
(en)
|
2009-08-11 |
2021-06-09 |
상가모 테라퓨틱스, 인코포레이티드 |
Organisms homozygous for targeted modification
|
|
UA109418C2
(en)
|
2009-10-22 |
2015-08-25 |
|
Zinc Finger Protein Designed for Plant Genes Involved in Fatty Acid Biosynthesis
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CN102939383B
(en)
|
2009-12-30 |
2015-04-29 |
先锋国际良种公司 |
Methods and compositions for targeted polynucleotide modification
|
|
WO2011090804A1
(en)
|
2010-01-22 |
2011-07-28 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
|
WO2011097036A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
|
EP2534163B1
(en)
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
JP5952263B2
(en)
|
2010-04-26 |
2016-07-13 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Genome editing of the ROSA locus using zinc finger nuclease
|
|
WO2011139349A1
(en)
|
2010-05-03 |
2011-11-10 |
Sangamo Biosciences, Inc. |
Compositions for linking zinc finger modules
|
|
CN103025344B
(en)
|
2010-05-17 |
2016-06-29 |
桑格摩生物科学股份有限公司 |
Novel DNA-associated proteins and application thereof
|
|
JP6050230B2
(en)
|
2010-07-21 |
2016-12-21 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Methods and compositions for modification of HLA loci
|
|
US9566352B2
(en)
|
2010-09-27 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
BR112013008230A2
(en)
|
2010-10-05 |
2016-06-14 |
Int Inst Cancer Immunology Inc |
method to activate helper t cell
|
|
ES2562421T3
(en)
*
|
2010-10-12 |
2016-03-04 |
The Children's Hospital Of Philadelphia |
Methods and compositions to treat hemophilia B
|
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
CN103415532B
(en)
*
|
2011-01-20 |
2016-05-04 |
万德-生物技术及制药有限公司 |
Anti-oxidant, anti-inflammatory, radioresistance, metalchelated compound and uses thereof
|
|
MX2013010911A
(en)
|
2011-03-23 |
2015-03-03 |
Pioneer Hi Bred Int |
Methods for producing a complex transgenic trait locus.
|
|
CN103492578B
(en)
|
2011-04-27 |
2016-10-19 |
阿迈瑞斯公司 |
Method for genomic modification
|
|
CN104080914A
(en)
|
2011-06-21 |
2014-10-01 |
先锋国际良种公司 |
Methods and compositions for producing male sterile plants
|
|
EP2732038B1
(en)
|
2011-07-15 |
2018-09-05 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
CA2841541C
(en)
|
2011-07-25 |
2019-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
SG10201811736QA
(en)
|
2011-09-21 |
2019-02-27 |
Sangamo Therapeutics Inc |
Methods and compositions for regulation of transgene expression
|
|
WO2013063315A2
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
JP6144691B2
(en)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス， インコーポレイテッド |
Modified DNA binding proteins and uses thereof
|
|
EP2820159B1
(en)
|
2012-02-29 |
2019-10-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating huntington's disease
|
|
KR102091298B1
(en)
|
2012-05-02 |
2020-03-19 |
다우 아그로사이언시즈 엘엘씨 |
Targeted modification of malate dehydrogenase
|
|
JP6559063B2
(en)
|
2012-05-07 |
2019-08-14 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
EP3444342B1
(en)
|
2012-07-11 |
2020-05-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
EP2872154B1
(en)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Methods and compositions for delivery of biologics
|
|
CN104717970A
(en)
|
2012-07-23 |
2015-06-17 |
万德-生物技术及制药有限公司 |
Glutathione-elevating compositions and uses thereof
|
|
EP2877194A4
(en)
|
2012-07-25 |
2016-03-16 |
Oneday Biotech And Pharma Ltd |
Compositions and methods for increasing carnitine level in muscle tissues
|
|
KR102474010B1
(en)
|
2012-08-29 |
2022-12-02 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for treatment of a genetic condition
|
|
US9914930B2
(en)
|
2012-09-07 |
2018-03-13 |
Dow Agrosciences Llc |
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
JP6401704B2
(en)
|
2012-10-10 |
2018-10-10 |
サンガモ セラピューティクス， インコーポレイテッド |
Compounds that modify T cells and uses thereof
|
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
RU2015128052A
(en)
|
2012-12-13 |
2017-01-19 |
Дау Агросайенсиз Ллс |
PRECISE TARGETING OF GENES REGARDING SPECIFIC LOCUS OF CORN
|
|
JP6530192B2
(en)
|
2012-12-17 |
2019-06-12 |
大塚製薬株式会社 |
Method of activating helper T cells
|
|
EP3623463B1
(en)
|
2013-02-07 |
2021-10-20 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
JP6491113B2
(en)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
CA2906970C
(en)
|
2013-03-21 |
2021-05-18 |
Ospedale San Raffaele Srl |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2981166B1
(en)
|
2013-04-05 |
2020-09-09 |
Dow AgroSciences LLC |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
CA2910427C
(en)
|
2013-05-10 |
2024-02-20 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
JP6588438B2
(en)
|
2013-08-28 |
2019-10-09 |
サンガモ セラピューティクス， インコーポレイテッド |
Composition for linking a DNA binding domain and a cleavage domain
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN105899665B
(en)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
The delivering method and composition being transformed for nuclease-mediated genome project
|
|
TWI721478B
(en)
|
2013-11-04 |
2021-03-11 |
美商陶氏農業科學公司 |
Optimal maize loci
|
|
TWI659103B
(en)
|
2013-11-04 |
2019-05-11 |
陶氏農業科學公司 |
Optimal soybean loci
|
|
EP3066202B1
(en)
|
2013-11-04 |
2021-03-03 |
Dow AgroSciences LLC |
Optimal soybean loci
|
|
EP3065540B1
(en)
|
2013-11-04 |
2021-12-15 |
Corteva Agriscience LLC |
Optimal maize loci
|
|
US10369201B2
(en)
|
2013-11-11 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's disease
|
|
SI3068881T1
(en)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
JP6535684B2
(en)
|
2013-12-09 |
2019-06-26 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for genome manipulation
|
|
AU2014368982B2
(en)
|
2013-12-19 |
2021-03-25 |
Amyris, Inc. |
Methods for genomic integration
|
|
CA2939942A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
|
CA2954201A1
(en)
|
2014-07-08 |
2016-01-14 |
Vib Vzw |
Means and methods to increase plant yield
|
|
EP3169778B1
(en)
|
2014-07-14 |
2023-10-25 |
Washington State University |
Nanos knock-out that ablates germline cells
|
|
US11278572B2
(en)
|
2014-07-18 |
2022-03-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
EP3878948A1
(en)
|
2014-09-16 |
2021-09-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
WO2016161446A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
SG10202112057QA
(en)
|
2015-05-12 |
2021-12-30 |
Sangamo Therapeutics Inc |
Nuclease-mediated regulation of gene expression
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CN108025034B
(en)
*
|
2015-07-15 |
2022-09-30 |
新加坡科技研究局 |
Regulation of hepatitis b virus replication
|
|
EP4361279A2
(en)
|
2015-08-06 |
2024-05-01 |
The Curators of the University of Missouri |
Pathogen-resistant animals having modified cd163 genes
|
|
EP3352776A4
(en)
|
2015-09-23 |
2019-03-13 |
Sangamo Therapeutics, Inc. |
Htt repressors and uses thereof
|
|
CA3004349A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
|
SG11201805680SA
(en)
|
2016-01-15 |
2018-07-30 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of neurologic disease
|
|
JP7012650B2
(en)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
Composition for linking DNA binding domain and cleavage domain
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
WO2017165655A1
(en)
|
2016-03-23 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
US11293033B2
(en)
|
2016-05-18 |
2022-04-05 |
Amyris, Inc. |
Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
|
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
CA3031818A1
(en)
|
2016-07-27 |
2018-02-01 |
Case Western Reserve University |
Compounds and methods of promoting myelination
|
|
US11193136B2
(en)
|
2016-08-09 |
2021-12-07 |
Vib Vzw |
Cellulose synthase inhibitors and mutant plants
|
|
BR112019003327A2
(en)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics Inc |
specific target engineered nucleases
|
|
IL264639B2
(en)
|
2016-08-24 |
2024-01-01 |
Sangamo Therapeutics Inc |
Regulation of globulin gene expression using engineered zinc finger nucleases
|
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
DK3757120T3
(en)
|
2016-10-04 |
2022-07-25 |
Prec Biosciences Inc |
CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY MODIFIED CELLS
|
|
CN110022904B
(en)
|
2016-10-20 |
2024-04-19 |
桑格摩生物治疗股份有限公司 |
Methods and compositions for treating brile disease
|
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
AU2017367722B2
(en)
|
2016-12-01 |
2024-02-01 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
|
CA3046199A1
(en)
|
2016-12-08 |
2018-06-14 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
|
CN110582302A
(en)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
Compositions and methods for nucleic acid and/or protein payload delivery
|
|
SG11201906948UA
(en)
|
2017-04-20 |
2019-08-27 |
Univ Oregon Health & Science |
Human gene correction
|
|
AU2018261366A1
(en)
|
2017-05-03 |
2019-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
|
|
CA3062698A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
US11053484B2
(en)
|
2017-06-30 |
2021-07-06 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
|
US20200239544A1
(en)
|
2017-10-03 |
2020-07-30 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
|
WO2019089913A1
(en)
|
2017-11-01 |
2019-05-09 |
Precision Biosciences, Inc. |
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
SG11202004003YA
(en)
|
2017-11-09 |
2020-05-28 |
Sangamo Therapeutics Inc |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
|
KR20200110687A
(en)
|
2018-01-17 |
2020-09-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Quinoxalinone compounds, compositions, methods and kits for increasing genome editing efficiency
|
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
IL276080B2
(en)
|
2018-01-17 |
2023-10-01 |
Vertex Pharma |
Dna-pk inhibitor compounds, compositions comprising same and uses thereof
|
|
AU2019218118A1
(en)
|
2018-02-08 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
CN112313246A
(en)
|
2018-04-18 |
2021-02-02 |
桑格摩生物治疗股份有限公司 |
Zinc finger protein compositions for modulating Huntingtin (HTT)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CA3109592A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
CN113015741A
(en)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
Programmed cell death 1(PD1) specific nucleases
|
|
EP3898661A1
(en)
|
2018-12-21 |
2021-10-27 |
Precision BioSciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
AU2020205717A1
(en)
|
2019-01-11 |
2021-08-12 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN112805026A
(en)
|
2019-02-06 |
2021-05-14 |
桑格摩生物治疗股份有限公司 |
Methods for treating mucopolysaccharidosis type I
|
|
US20220145330A1
(en)
|
2019-02-10 |
2022-05-12 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Modified mitochondrion and methods of use thereof
|
|
SG11202110776TA
(en)
|
2019-04-02 |
2021-10-28 |
Sangamo Therapeutics Inc |
Methods for the treatment of beta-thalassemia
|
|
CA3135799A1
(en)
|
2019-04-03 |
2020-10-08 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
|
WO2020206231A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
TW202104249A
(en)
|
2019-04-23 |
2021-02-01 |
美商聖加莫治療股份有限公司 |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
|
BR112021021200A2
(en)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides, and methods
|
|
BR112021021075A2
(en)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
JP2022544825A
(en)
|
2019-08-20 |
2022-10-21 |
プレシジョン バイオサイエンシズ，インク． |
Lymphocyte-depleting administration regimens for cellular immunotherapy
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP4041754A1
(en)
|
2019-10-02 |
2022-08-17 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
US20230002459A1
(en)
|
2019-10-02 |
2023-01-05 |
Sangamo Therapeutics, Inc. |
Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
|
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
EP4051787A1
(en)
|
2019-11-01 |
2022-09-07 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
|
US20230036065A1
(en)
|
2019-12-06 |
2023-02-02 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
AU2021209699A1
(en)
|
2020-01-22 |
2022-07-21 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing tau expression
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
US20230263121A1
(en)
|
2020-03-31 |
2023-08-24 |
Elo Life Systems |
Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
|
|
AU2021268253A1
(en)
|
2020-05-06 |
2022-12-08 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
JP2023525510A
(en)
|
2020-05-06 |
2023-06-16 |
セレクティス ソシエテ アノニム |
Methods of genetically modifying cells for delivery of therapeutic proteins
|
|
US20230183664A1
(en)
|
2020-05-11 |
2023-06-15 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
KR20230022868A
(en)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Method for producing donor-batch cells expressing a recombinant acceptor
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN116261594A
(en)
|
2020-09-25 |
2023-06-13 |
桑格摩生物治疗股份有限公司 |
Zinc finger fusion proteins for nucleobase editing
|
|
CA3197644A1
(en)
|
2020-10-02 |
2022-04-07 |
Sangamo Therapeutics, Inc. |
Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
MX2023004761A
(en)
|
2020-10-23 |
2023-07-17 |
Elo Life Systems Inc |
Methods for producing vanilla plants with improved flavor and agronomic production.
|
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
EP4243609A1
(en)
|
2020-11-16 |
2023-09-20 |
Pig Improvement Company UK Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
US20240141311A1
(en)
|
2021-04-22 |
2024-05-02 |
North Carolina State University |
Compositions and methods for generating male sterile plants
|
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
|
CA3235185A1
(en)
|
2021-10-19 |
2023-04-27 |
Cassandra GORSUCH |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023091910A1
(en)
|
2021-11-16 |
2023-05-25 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023122722A1
(en)
|
2021-12-22 |
2023-06-29 |
Sangamo Therapeutics, Inc. |
Novel zinc finger fusion proteins for nucleobase editing
|
|
WO2023131616A1
(en)
|
2022-01-05 |
2023-07-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|